EGFR and non-small cell lung carcinoma: Numerous studies have effectively employed cBioPortal (76–78); in particular, Jiao et al. (79) evaluated the prognostic value of TP53 and its correlation with EGFR mutations in advanced non-small-cell lung cancer (NSCLC).